How magnetic brain stimulation helped one man beat his decades-long struggle with depression

Credit: Boston Globe
Credit: Boston Globe

When Tommy Van Brocklin signed up for a trial of a special type of magnetic brain stimulation therapy that could potentially ease his depression, he had already been living with the mood disorder for 45 years.

Van Brocklin, 60, first underwent an MRI that located the part of his brain that regulates executive functions such as problem-solving and inhibits unwanted responses.

Then for five days, for 10-minute sessions 10 times each day, doctors used repeated pulses to stimulate the part of his brain that could impact his depression.

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.

The treatment, called SAINT, is an intensive, individualized form of transcranial magnetic stimulation (TMS). In the new trial, researchers worked with 29 individuals who had severe depression that was resistant to other treatments. About half of the participants received SAINT. The other half had a placebo that was meant to mimic the real treatment with a magnetic coil that felt like a magnetic pulse

The relief came quickly, within days, and was successful for 78.6% of the treatment group. They were found to be no longer depressed in standard evaluations. Side effects were temporary fatigue and headaches.

This is an excerpt. Read the original post here. 

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT Image May 10, 2026, 08_16_59 PM 2
Overmedicalization? RFK Jr.’s antidepressant crackdown raises conflict questions over his fee stake in Wisner Baum, the tort firm built on suing drug makers
Picture1-5
Science Disinformation Gap: The transatlantic battle over social media and censorship
Screenshot-2026-05-08-at-3.40.33-PM
Seeds of power: China turns to genetic engineering to become global superpower
Screenshot-2026-05-01-at-1.29.41-PM
Viewpoint: What happens when whole grains meet modern food manufacturing? Labels don’t tell the whole story.
ChatGPT-Image-Apr-13-2026-02_20_22-PM
Viewpoint: Misinformation infodemic? Why assessing evidence is so challenging 
Picture1-14
When superbugs threaten vulnerable children: Can AI help solve antibiotic resistance?
S
As vaccine rejectionism spreads, measles may be taking a more dangerous turn
Farmers can talk to plants
Farmers are a major source of misinformation—about farming
Screenshot 2026-05-08 at 3.01
Transforming farming and nutrition with AI and robotics? Larry Ellison’s half-billion-dollar Hawaii greenhouse dream goes bust
Screenshot-2026-04-20-at-2.26.27-PM
Viewpoint — Food-fear world: The latest activist scientists campaign: Cancer-causing additives
ChatGPT-Image-May-8-2026-01_41_33-PM-3
Viewpoint: Surge of climate misinformation traced to right wing and anti-wind activists 
ChatGPT-Image-Mar-27-2026-11_47_30-AM-2
FDA’s expedited drug reviews are hailed in some quarters but other approval practices are problematic
Screenshot-2026-03-13-at-12.14.04-PM
The FDA wants to make many popular prescription drugs OTC—a great idea. Here’s why it’s unlikely to happen
Screenshot-2026-04-12-135256
Bixonimania: The fake disease scam that AI swallowed whole
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.